

BAXTER INTERNATIONAL INC.
Consolidated Statements of Income
Three Months Ended June 30, 2011 and 2010
(unaudited)
(in millions, except per share and percentage data)

	Three Months Ended June 30,		Change
	2011	2010	
NET SALES	\$3,536	\$3,194	11%
COST OF SALES	1,701	1,556	9%
GROSS MARGIN	1,835	1,638	12%
<i>% of Net Sales</i>	<i>51.9%</i>	<i>51.3%</i>	<i>0.6 pts</i>
MARKETING AND ADMINISTRATIVE EXPENSES	765	721 ^A	6%
<i>% of Net Sales</i>	<i>21.6%</i>	<i>22.6%</i>	<i>(1.0 pt)</i>
RESEARCH AND DEVELOPMENT EXPENSES	239	219	9%
<i>% of Net Sales</i>	<i>6.8%</i>	<i>6.9%</i>	<i>(0.1 pt)</i>
NET INTEREST EXPENSE	15	25	(40%)
OTHER EXPENSE, NET	13	3	N/M
PRE-TAX INCOME	803	670	20%
INCOME TAX EXPENSE	174	133	31%
<i>% of Pre-Tax Income</i>	<i>21.7%</i>	<i>19.9%</i>	<i>1.8 pts</i>
NET INCOME	629	537	17%
LESS: NONCONTROLLING INTERESTS	14	2	N/M
NET INCOME ATTRIBUTABLE TO BAXTER	\$615	\$535	15%
BASIC EPS	\$1.08	\$0.90	20%
DILUTED EPS	\$1.07	\$0.90	19%
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING			
Basic	570	593	
Diluted	575	596	
ADJUSTED PRE-TAX INCOME (excluding specified item)	\$803	\$698 ^B	15%
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER (excluding specified item)	\$615	\$557 ^B	10%
ADJUSTED DILUTED EPS (excluding specified item)	\$1.07	\$0.93 ^B	15%

^A Marketing and administrative expenses in 2010 included a charge of \$28 million (\$22 million, or \$0.03 per diluted share, on an after-tax basis) to write down accounts receivable in Greece, principally as a result of the anticipated settlement of certain accounts receivable with the Greek government.

^B Refer to page 8 for a description of the adjustment and a reconciliation to generally accepted accounting principles (GAAP) measures.

BAXTER INTERNATIONAL INC.
Note to Consolidated Statements of Income
Three Months Ended June 30, 2011 and 2010
Description of Adjustment and Reconciliation of GAAP to Non-GAAP Measures
(unaudited)
(in millions, except per share and percentage data)

The company's GAAP results for the three months ended June 30, 2010 included a specified item which impacted the GAAP results as follows:

	Three Months Ended June 30,				Change ³
	2011	2010			
	GAAP ¹	GAAP	Greece receivable charge ²	Excluding specified item	
NET SALES	\$3,536	\$ 3,194	\$ -	\$3,194	11%
COST OF SALES	1,701	1,556	-	1,556	9%
GROSS MARGIN	1,835	1,638	-	1,638	12%
<i>% of Net Sales</i>	<i>51.9%</i>	<i>51.3%</i>		<i>51.3%</i>	<i>0.6 pts</i>
MARKETING AND ADMINISTRATIVE EXPENSES	765	721	(28)	693	10%
<i>% of Net Sales</i>	<i>21.6%</i>	<i>22.6%</i>		<i>21.7%</i>	<i>(0.1 pt)</i>
RESEARCH AND DEVELOPMENT EXPENSES	239	219	-	219	9%
<i>% of Net Sales</i>	<i>6.8%</i>	<i>6.9%</i>		<i>6.9%</i>	<i>(0.1 pt)</i>
NET INTEREST EXPENSE	15	25	-	25	(40%)
OTHER EXPENSE, NET	13	3	-	3	N/M
PRE-TAX INCOME	803	670	28	698	15%
INCOME TAX EXPENSE	174	133	6	139	25%
<i>% of Pre-Tax Income</i>	<i>21.7%</i>	<i>19.9%</i>		<i>19.9%</i>	<i>1.8 pts</i>
NET INCOME	629	537	22	559	13%
LESS: NONCONTROLLING INTERESTS	14	2	-	2	N/M
NET INCOME ATTRIBUTABLE TO BAXTER	\$615	\$535	\$22	\$557	10%
BASIC EPS	\$1.08	\$0.90	\$0.04	\$0.94	15%
DILUTED EPS	\$1.07	\$0.90	\$0.03	\$0.93	15%
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING					
Basic	570	593		593	
Diluted	575	596		596	

¹ There were no specified items included in the 2011 GAAP results.

² Marketing and administrative expenses in 2010 included a charge of \$28 million (\$22 million, or \$0.03 per diluted share, on an after-tax basis) to write down accounts receivable in Greece, principally as a result of the anticipated settlement of certain accounts receivable with the Greek government.

³ Represents the percentage change between the 2011 GAAP results and the 2010 results excluding the specified item.

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.

BAXTER INTERNATIONAL INC.
Consolidated Statements of Income
Six Months Ended June 30, 2011 and 2010
(unaudited)
(in millions, except per share and percentage data)

	Six Months Ended June 30,		Change
	2011	2010	
NET SALES	\$6,820	\$6,121 ^A	11%
COST OF SALES	3,310	3,440 ^A	(4%)
GROSS MARGIN	3,510	2,681	31%
<i>% of Net Sales</i>	<i>51.5%</i>	<i>43.8%</i>	<i>7.7 pts</i>
MARKETING AND ADMINISTRATIVE EXPENSES	1,481	1,404 ^B	5%
<i>% of Net Sales</i>	<i>21.7%</i>	<i>22.9%</i>	<i>(1.2 pts)</i>
RESEARCH AND DEVELOPMENT EXPENSES	453	446	2%
<i>% of Net Sales</i>	<i>6.6%</i>	<i>7.3%</i>	<i>(0.7 pts)</i>
NET INTEREST EXPENSE	25	44	(43%)
OTHER EXPENSE, NET	17	5	N/M
PRE-TAX INCOME	1,534	782	96%
INCOME TAX EXPENSE	328	305 ^C	8%
<i>% of Pre-Tax Income</i>	<i>21.4%</i>	<i>39.0%</i>	<i>(17.6 pts)</i>
NET INCOME	1,206	477	153%
LESS: NONCONTROLLING INTERESTS	21	5	N/M
NET INCOME ATTRIBUTABLE TO BAXTER	\$1,185	\$472	151%
BASIC EPS	\$2.07	\$0.79	162%
DILUTED EPS	\$2.05	\$0.78	163%
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING			
Basic	573	597	
Diluted	578	602	
ADJUSTED PRE-TAX INCOME (excluding specified items)	\$1,534	\$1,398 ^D	10%
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER (excluding specified items)	\$1,185	\$1,121 ^D	6%
ADJUSTED DILUTED EPS (excluding specified items)	\$2.05	\$1.86 ^D	10%

^A Net sales and cost of sales in the first quarter of 2010 included a charge totaling \$588 million, or \$0.98 per diluted share, which related to the recall of COLLEAGUE infusion pumps from the U.S. market and other actions the company is undertaking outside of the United States, for which there was no net tax benefit recognized.

^B Marketing and administrative expenses in the second quarter of 2010 included a charge of \$28 million (\$22 million, or \$0.03 per diluted share, on an after-tax basis) to write down accounts receivable in Greece, principally as a result of the anticipated settlement of certain accounts receivable with the Greek government.

^C Income tax expense in the first quarter of 2010 included a charge of \$39 million, or \$0.07 per diluted share, to write off a deferred tax asset as a result of a change in the tax treatment of reimbursements under the Medicare Part D retiree prescription drug subsidy program.

^D Refer to page 10 for a description of the adjustments and a reconciliation to GAAP measures.

BAXTER INTERNATIONAL INC.
Note to Consolidated Statements of Income
Six Months Ended June 30, 2011 and 2010
Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures
(unaudited)
(in millions, except per share and percentage data)

The company's GAAP results for the six months ended June 30, 2010 included specified items which impacted the GAAP results as follows:

	Six Months Ended June 30,				Change ³
	2011	2010			
	GAAP ¹	GAAP	Total specified items ²	Excluding specified items	
NET SALES	\$6,820	\$6,121	\$ 213	\$6,334	8%
COST OF SALES	3,310	3,440	(375)	3,065	8%
GROSS MARGIN	3,510	2,681	588	3,269	7%
<i>% of Net Sales</i>	<i>51.5%</i>	<i>43.8%</i>		<i>51.6%</i>	<i>(0.1 pt)</i>
MARKETING AND ADMINISTRATIVE EXPENSES	1,481	1,404	(28)	1,376	8%
<i>% of Net Sales</i>	<i>21.7%</i>	<i>22.9%</i>		<i>21.7%</i>	<i>0 pts</i>
RESEARCH AND DEVELOPMENT EXPENSES	453	446	-	446	2%
<i>% of Net Sales</i>	<i>6.6%</i>	<i>7.3%</i>		<i>7.0%</i>	<i>(0.4 pts)</i>
NET INTEREST EXPENSE	25	44	-	44	(43%)
OTHER EXPENSE, NET	17	5	-	5	N/M
PRE-TAX INCOME	1,534	782	616	1,398	10%
INCOME TAX EXPENSE	328	305	(33)	272	21%
<i>% of Pre-Tax Income</i>	<i>21.4%</i>	<i>39.0%</i>		<i>19.5%</i>	<i>1.9 pts</i>
NET INCOME	1,206	477	649	1,126	7%
LESS: NONCONTROLLING INTERESTS	21	5	-	5	N/M
NET INCOME ATTRIBUTABLE TO BAXTER	\$1,185	\$472	\$649	\$1,121	6%
BASIC EPS	\$2.07	\$0.79	\$1.09	\$1.88	10%
DILUTED EPS	\$2.05	\$0.78	\$1.08	\$1.86	10%
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING					
Basic	573	597		597	
Diluted	578	602		602	

¹ There were no specified items included in the 2011 GAAP results.

² Net sales and cost of sales in the first quarter of 2010 included a charge totaling \$588 million, or \$0.98 per diluted share, which related to the recall of COLLEAGUE infusion pumps from the U.S. market and other actions the company is undertaking outside of the United States, for which there was no net tax benefit recognized. Marketing and administrative expenses in the second quarter of 2010 included a charge of \$28 million (\$22 million, or \$0.03 per diluted share, on an after-tax basis) to write down accounts receivable in Greece, principally as a result of the anticipated settlement of certain accounts receivable with the Greek government. Income tax expense in the first quarter of 2010 included a charge of \$39 million, or \$0.07 per diluted share, to write off a deferred tax asset as a result of a change in the tax treatment of reimbursements under the Medicare Part D retiree prescription drug subsidy program.

³ Represents the percentage change between the 2011 GAAP results and the 2010 results excluding specified items.

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.

BAXTER INTERNATIONAL INC.
Cash Flows from Operations and Changes in Net Debt
(unaudited)
(\$ in millions)

Cash Flows from Operations (Brackets denote cash outflows)	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2011	2010	2011	2010
Net income	\$629	\$537	\$1,206	\$477
Adjustments				
Depreciation and amortization	169	169	327	335
Deferred income taxes	69	29	160	120 ^A
Stock compensation	33	33	61	63
Realized excess tax benefits from stock issued under employee benefit plans	(8)	(3)	(13)	(34)
COLLEAGUE infusion pump charge	-	-	-	588
Greece receivable charge	-	28	-	28
Other	10	(4)	18	5
Changes in balance sheet items				
Accounts and other current receivables	(89)	(5)	(157)	(38)
Inventories	(153)	(25)	(214)	(119)
Accounts payable and accrued liabilities	11	(51)	(124)	(152)
Infusion pump and business optimization payments	(87)	(18)	(147)	(41)
Other	48	93	(114) ^B	(170) ^B
Cash flows from operations	\$632	\$783	\$1,003	\$1,062
Changes in Net Debt				
Increase (decrease)				
Net debt, beginning of period	\$2,206	\$2,080	\$1,702	\$1,365
Cash flows from operations	(632)	(783)	(1,003)	(1,062)
Capital expenditures	210	237	408	467
Dividends	178	174	358	348
Proceeds from stock issued under employee benefit plans	(162)	(61)	(291)	(201)
Purchases of treasury stock	478	677	1,115	1,112
Acquisitions and investments	188 ^C	20	202 ^C	254 ^C
Divestiture and other	(106)	-	(106)	-
Other, including the effect of exchange rate changes	22	170	(3)	231
Increase in net debt	176	434	680	1,149
Net debt, June 30	\$2,382	\$2,514	\$2,382	\$2,514
Key statistics, June 30:				
Days sales outstanding	57.8	54.3	57.8	54.3
Inventory turns	2.5	2.5	2.5	2.5
Selected balance sheet information:			June 30, 2011	December 31, 2010
Cash and equivalents			\$2,018	\$2,685
Accounts and other current receivables			\$2,491	\$2,265
Inventories			\$2,648	\$2,371
Accounts payable and accrued liabilities			\$4,009	\$4,017

^A Deferred income taxes in the first quarter of 2010 included a charge of \$39 million to write off a deferred tax asset as a result of a change in the tax treatment of reimbursements under the Medicare Part D retiree prescription drug subsidy program.

^B Other cash flows from operations included planned contributions to the company's pension plan in the United States of \$150 million and \$300 million in the first quarters of 2011 and 2010, respectively.

^C Acquisitions and investments in 2011 and 2010 principally related to the second quarter 2011 acquisition of Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in the United States, and the first quarter 2010 acquisition of ApaTech Limited, an orthobiologic products company based in the United Kingdom.

BAXTER INTERNATIONAL INC.
Net Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
(\$ in millions)

	Q2 2011	Q2 2010	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2011	YTD 2010	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
United States	\$687	\$636	8%	8%	\$1,371	\$1,246	10%	10%
International	866	722	20%	11%	1,590	1,474	8%	5%
Total BioScience	\$1,553	\$1,358	14%	10%	\$2,961	\$2,720	9%	7%
Medical Products¹								
United States ²	\$722	\$710	2%	2%	\$1,452	\$1,384	5%	5%
International	1,251	1,114	12%	4%	2,389	2,206	8%	4%
Total Medical Products - Adjusted²	\$1,973	\$1,824	8%	3%	\$3,841	\$3,590	7%	4%
COLLEAGUE infusion pump charge ²						(213)		
Total Medical Products - GAAP²	\$1,973	\$1,824	8%	3%	\$3,841	\$3,377	14%	11%
Transfusion Therapies³								
United States	\$9	\$9	0%	0%	\$17	\$18	(6%)	(6%)
International	1	3	(67%)	(67%)	1	6	(83%)	(83%)
Total Transfusion Therapies	\$10	\$12	(17%)	(17%)	\$18	\$24	(25%)	(25%)
Baxter International Inc.								
United States ²	\$1,418	\$1,355	5%	5%	\$2,840	\$2,648	7%	7%
International	2,118	1,839	15%	7%	3,980	3,686	8%	4%
Total Baxter - Adjusted²	\$3,536	\$3,194	11%	6%	\$6,820	\$6,334	8%	5%
COLLEAGUE infusion pump charge ²						(213)		
Total Baxter - GAAP²	\$3,536	\$3,194	11%	6%	\$6,820	\$6,121	11%	9%

¹ Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

² GAAP net sales in the first quarter of 2010 included a charge of \$213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 16 for a reconciliation to GAAP measures.

³ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies (TT) business after the February 2007 divestiture.

BAXTER INTERNATIONAL INC.
GAAP Key Product Line Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
(\$ in millions)

	GAAP Q2 2011	GAAP Q2 2010	% Growth @ Actual Rates	% Growth @ Constant Rates	GAAP YTD 2011	GAAP YTD 2010	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$570	\$525	9%	3%	\$1,082	\$1,035	5%	2%
Plasma Proteins	363	314	16%	11%	671	606	11%	9%
Antibody Therapy	381	310	23%	21%	755	632	19%	19%
Regenerative Medicine	147	133	11%	6%	287	252	14%	12%
Other ¹	92	76	21%	12%	166	195	(15%)	(19%)
Total BioScience	\$1,553	\$1,358	14%	10%	\$2,961	\$2,720	9%	7%
Medical Products ²								
Renal	\$633	\$585	8%	2%	\$1,220	\$1,169	4%	0%
Global Injectables	506	472	7%	3%	1,023	923	11%	9%
IV Therapies	452	418	8%	3%	880	809	9%	6%
Infusion Systems ³	233	216	8%	5%	444	212	110%	106%
Anesthesia	143	130	10%	8%	261	257	2%	0%
Other	6	3	100%	25%	13	7	86%	20%
Total Medical Products ³	\$1,973	\$1,824	8%	3%	\$3,841	\$3,377	14%	11%
Transfusion Therapies ⁴	\$10	\$12	(17%)	(17%)	\$18	\$24	(25%)	(25%)
Total Baxter ³	\$3,536	\$3,194	11%	6%	\$6,820	\$6,121	11%	9%

¹ Principally includes vaccines and sales of plasma to third parties.

² Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

³ GAAP net sales in the first quarter of 2010 included a charge of \$213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 16 for a reconciliation to GAAP measures.

⁴ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.

BAXTER INTERNATIONAL INC.
Adjusted Key Product Line Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
(\$ in millions)

	GAAP Q2 2011 ¹	GAAP Q2 2010 ¹	% Growth @ Actual Rates	% Growth @ Constant Rates	GAAP YTD 2011 ¹	Adjusted YTD 2010	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$570	\$525	9%	3%	\$1,082	\$1,035	5%	2%
Plasma Proteins	363	314	16%	11%	671	606	11%	9%
Antibody Therapy	381	310	23%	21%	755	632	19%	19%
Regenerative Medicine	147	133	11%	6%	287	252	14%	12%
Other ²	92	76	21%	12%	166	195	(15%)	(19%)
Total BioScience	\$1,553	\$1,358	14%	10%	\$2,961	\$2,720	9%	7%
Medical Products ³								
Renal	\$633	\$585	8%	2%	\$1,220	\$1,169	4%	0%
Global Injectables	506	472	7%	3%	1,023	923	11%	9%
IV Therapies	452	418	8%	3%	880	809	9%	6%
Infusion Systems - Adjusted ⁴	233	216	8%	5%	444	425	4%	3%
Anesthesia	143	130	10%	8%	261	257	2%	0%
Other	6	3	100%	25%	13	7	86%	20%
Total Medical Products - Adjusted ⁴	\$1,973	\$1,824	8%	3%	\$3,841	\$3,590	7%	4%
Transfusion Therapies ⁵	\$10	\$12	(17%)	(17%)	\$18	\$24	(25%)	(25%)
Total Baxter - Adjusted ⁴	\$3,536	\$3,194	11%	6%	\$6,820	\$6,334	8%	5%

¹ There were no adjustments included in the 2011 GAAP results or the Q2 2010 GAAP results.

² Principally includes vaccines and sales of plasma to third parties.

³ Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

⁴ Adjusted net sales in the first quarter of 2010 excluded a charge of \$213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 16 for a reconciliation to GAAP measures.

⁵ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.

BAXTER INTERNATIONAL INC.
Key Product Line Sales by U.S. and International
Three-Month Periods Ending June 30, 2011 and 2010
(unaudited)
(\$ in millions)

	Q2 2011			Q2 2010			% Growth		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
BioScience									
Recombinants	\$239	\$331	\$570	\$233	\$292	\$525	3%	13%	9%
Plasma Proteins	103	260	363	110	204	314	(6%)	27%	16%
Antibody Therapy	261	120	381	211	99	310	24%	21%	23%
Regenerative Medicine	78	69	147	76	57	133	3%	21%	11%
Other ¹	6	86	92	6	70	76	0%	23%	21%
Total BioScience	\$687	\$866	\$1,553	\$636	\$722	\$1,358	8%	20%	14%
Medical Products²									
Renal	\$97	\$536	\$633	\$98	\$487	\$585	(1%)	10%	8%
Global Injectables	255	251	506	263	209	472	(3%)	20%	7%
IV Therapies	144	308	452	134	284	418	7%	8%	8%
Infusion Systems	137	96	233	132	84	216	4%	14%	8%
Anesthesia	88	55	143	84	46	130	5%	20%	10%
Other	1	5	6	(1)	4	3	N/M	25%	100%
Total Medical Products	\$722	\$1,251	\$1,973	\$710	\$1,114	\$1,824	2%	12%	8%
Transfusion Therapies³	\$9	\$1	\$10	\$9	\$3	\$12	0%	(67%)	(17%)
Total Baxter	\$1,418	\$2,118	\$3,536	\$1,355	\$1,839	\$3,194	5%	15%	11%

¹ Principally includes vaccines and sales of plasma to third parties.

² Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

³ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.

BAXTER INTERNATIONAL INC.
Reconciliation of GAAP to Non-GAAP Net Sales Measures
Periods Ending June 30, 2011 and 2010
(unaudited)
(\$ in millions)

The company's GAAP net sales results for the six months ended June 30, 2010 included a \$213 million charge related to the recall of COLLEAGUE infusion pumps, which impacted GAAP net sales as follows:

	2011 YTD			2010 YTD			% Growth @ Actual Rates			% Growth @ Constant Rates		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
Infusion Systems - GAAP			\$444			\$212			110%			106%
COLLEAGUE infusion pump charge						213						
Infusion Systems - Adjusted			\$444			\$425			4%			3%
Total Medical Products - GAAP	\$1,452	\$2,389	\$3,841	\$1,171	\$2,206	\$3,377	24%	8%	14%	24%	4%	11%
COLLEAGUE infusion pump charge				213		213						
Total Medical Products - Adjusted	\$1,452	\$2,389	\$3,841	\$1,384	\$2,206	\$3,590	5%	8%	7%	5%	4%	4%
Total Baxter - GAAP	\$2,840	\$3,980	\$6,820	\$2,435	\$3,686	\$6,121	17%	8%	11%	17%	4%	9%
COLLEAGUE infusion pump charge				213		213						
Total Baxter - Adjusted	\$2,840	\$3,980	\$6,820	\$2,648	\$3,686	\$6,334	7%	8%	8%	7%	4%	5%

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.